Thema: News: High-dose methotrexate in primary cns-lymphoma
News: High-dose methotrexate in primary cns-lymphoma
Anne[a]
14.08.2005 22:11:02
Ann Neurol. 2005 Jun;57(6):843-7.
NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.
Herrlinger U, Kuker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M; Neuro-Oncology Working Group of the German Society.
Department of General Neurology, Hertie Institute for Clinical Brain Research, Tubingen, Germany. ulrich.herrlinger@uni-tuebingen.de
The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherapy given at relapse (p = 0.11). Attention deficits were found in all six tested patients, and memory deficits in four patients. Two patients had normal, three had moderately restricted, and one had markedly restricted quality of life. Thus, high-dose methotrexate with deferred radiotherapy had only moderate efficacy and was associated with significant neurotoxicity in long-term surviving patients.
NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.
Herrlinger U, Kuker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M; Neuro-Oncology Working Group of the German Society.
Department of General Neurology, Hertie Institute for Clinical Brain Research, Tubingen, Germany. ulrich.herrlinger@uni-tuebingen.de
The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherapy given at relapse (p = 0.11). Attention deficits were found in all six tested patients, and memory deficits in four patients. Two patients had normal, three had moderately restricted, and one had markedly restricted quality of life. Thus, high-dose methotrexate with deferred radiotherapy had only moderate efficacy and was associated with significant neurotoxicity in long-term surviving patients.
Anne[a]
Timo[a]
18.08.2005 16:39:23
Der Versuch NOA-03 erforschte Hochdosis methotrexate alleine bei 37 Patienten mit hauptsächlichLymphom des zentralnervensystems. Das gesamte mittlere Überleben war 25 Monate. Nach 4 Jahren war die Rate von leukoencephalopathy bei den Patienten, die mehr als 12 Monate überleben, 58% mit und 10% ohne die Vollständiggehirn Strahlentherapie, die am Rückfall gegeben wurde (p = 0.11). Aufmerksamkeit Defizit wurde in allen sechs geprüften Patienten und im Gedächtnisdefizit bei vier Patienten gefunden. Zwei Patienten hatten Normal, hatten drei gemäßigt eingeschränkt, und man hatte deutlich Lebensqualität eingeschränkt. So hatte Hochdosis methotrexate mit aufgeschobener Strahlentherapie nur gemäßigte Wirksamkeit und war mit Neurotoxicität bei langfristigen überlebenden Patienten verbunden.
Timo[a]